Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Singhal, S.
Right arrow Articles by Albelda, S. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Singhal, S.
Right arrow Articles by Albelda, S. M.
Clinical Cancer Research Vol. 9, 3080-3097, August 2003
© 2003 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Gene Expression Profiling of Malignant Mesothelioma1

Sunil Singhal2, Rainer Wiewrodt2, Liliana D. Malden, Kunjlata M. Amin, Kimberly Matzie, Joseph Friedberg, John C. Kucharczuk, Leslie A. Litzky, Steven W. Johnson, Larry R. Kaiser and Steven M. Albelda3

Section of Thoracic Surgery, Department of Surgery [S. S., K. M. A., K. M., J. F., J. C. K., L. R. K.], and Departments of Pulmonary Medicine [R. W., L. D. M., S. M. A.], Pharmacology [S. W. J.], and Pathology and Laboratory Medicine [L. A. L.], University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104

Purpose: Malignant mesothelioma is a uniformly fatal cancer of the pleural and peritoneal spaces. Several challenging clinical problems include poor understanding of the pathophysiology, inaccurate diagnosis from tissue samples, and unsuccessful treatment strategies. The purpose of this study was to use microarray analysis to identify specific gene expression changes in mesothelioma compared with normal mesothelium.

Experimental Design: We performed gene expression analysis on mesothelioma tissue specimens from 16 patients and compared these to 4 control pleural tissue samples using cDNA microarray filters with 4132 clones. Multiple normalization and analysis approaches were used. Quantitative reverse transcription-PCR and immunohistochemistry were used to validate results.

Results: Genes (166) were significantly up-regulated, and 26 were down-regulated. Validation of 18 genes using real-time PCR confirmed array predictions in every case. Analysis revealed activation of several key pathways including genes involved in glucose metabolism, mRNA translation, and cytoskeletal remodeling. Expression profiling identified processes likely responsible for 18-fluoro-2-deoxy-glucose uptake and tumor localization by positron emission tomography, and a role for hypoxia-inducible factor-1 was suggested. Potentially important up-regulated genes included gp96, lung resistance-related protein, galectin-3 binding protein, the Mr 67,000 laminin receptor (on tumor vessels), and voltage-dependent anion channels. Prospective testing using reverse transcription-PCR confirmed up-regulation of these novel markers.

Conclusions: Expression profiling revealed marked up-regulation of energy, protein translation, and cytoskeletal remodeling pathways in mesothelioma. Additional genes that could be important in our understanding of the pathogenesis of mesothelioma, aiding in diagnosis, or improving targets for therapy were also identified.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
S. Romagnoli, E. Fasoli, V. Vaira, M. Falleni, C. Pellegrini, A. Catania, M. Roncalli, A. Marchetti, L. Santambrogio, G. Coggi, et al.
Identification of Potential Therapeutic Targets in Malignant Mesothelioma Using Cell-Cycle Gene Expression Analysis
Am. J. Pathol., March 1, 2009; 174(3): 762 - 770.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Vachani, M. Nebozhyn, S. Singhal, L. Alila, E. Wakeam, R. Muschel, C. A. Powell, P. Gaffney, B. Singh, M. S. Brose, et al.
A 10-Gene Classifier for Distinguishing Head and Neck Squamous Cell Carcinoma and Lung Squamous Cell Carcinoma
Clin. Cancer Res., May 15, 2007; 13(10): 2905 - 2915.
[Abstract] [Full Text] [PDF]


Home page
RadioGraphicsHome page
S. M. Tyszko, G. D. Marano, R. J. Tallaksen, and K. A. Gyure
Best Cases from the AFIP: Malignant Mesothelioma
RadioGraphics, January 1, 2007; 27(1): 259 - 264.
[Full Text] [PDF]


Home page
Cancer Res.Home page
D. D. Thomas, M. G. Espey, D. A. Pociask, L. A. Ridnour, S. Donzelli, and D. A. Wink
Asbestos Redirects Nitric Oxide Signaling through Rapid Catalytic Conversion to Nitrite
Cancer Res., December 15, 2006; 66(24): 11600 - 11604.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
F. Lopez-Rios, S. Chuai, R. Flores, S. Shimizu, T. Ohno, K. Wakahara, P. B. Illei, S. Hussain, L. Krug, M. F. Zakowski, et al.
Global Gene Expression Profiling of Pleural Mesotheliomas: Overexpression of Aurora Kinases and P16/CDKN2A Deletion as Prognostic Factors and Critical Evaluation of Microarray-Based Prognostic Prediction.
Cancer Res., March 15, 2006; 66(6): 2970 - 2979.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. W. Robinson and R. A. Lake
Advances in malignant mesothelioma.
N. Engl. J. Med., October 13, 2005; 353(15): 1591 - 1603.
[Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
C. Bolognesi, F. Martini, M. Tognon, R. Filiberti, M. Neri, E. Perrone, E. Landini, P. A. Canessa, G. P. Ivaldi, P. Betta, et al.
A Molecular Epidemiology Case Control Study on Pleural Malignant Mesothelioma
Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1741 - 1746.
[Abstract] [Full Text] [PDF]


Home page
GutHome page
K Schreiter, M Hausmann, T Spoettl, U G Strauch, F Bataille, J Schoelmerich, H Herfarth, W Falk, and G Rogler
Glycoprotein (gp) 96 expression: induced during differentiation of intestinal macrophages but impaired in Crohn's disease
Gut, July 1, 2005; 54(7): 935 - 943.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
G. J. Gordon, G. N. Rockwell, R. V. Jensen, J. G. Rheinwald, J. N. Glickman, J. P. Aronson, B. J. Pottorf, M. D. Nitz, W. G. Richards, D. J. Sugarbaker, et al.
Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling
Am. J. Pathol., June 1, 2005; 166(6): 1827 - 1840.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
E. Kettunen, A.G. Nicholson, B. Nagy, H. Wikman, J.K. Seppanen, T. Stjernvall, T. Ollikainen, V. Kinnula, S. Nordling, J. Hollmen, et al.
L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray
Carcinogenesis, January 1, 2005; 26(1): 17 - 25.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
N. J. Vogelzang
In Reply:
J. Clin. Oncol., October 15, 2004; 22(20): 4235 - 4236.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.